| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Kaposi’s sarcoma associated herpesvirus (KSHV) is an oncogenic DNA virus and classified in the gamma-herpesvirus subfamily. Kaposi's sarcoma and AIDS-related primary effusion lymphoma (PEL) is caused by KSHV infection. We have demonstrated that LANA protein suppresses the phosphorylation ability of GSK-3beta and stabilizes the protein-X by binding to the GSK-3beta. In addition, KSHV encoded vCyclin and LANA suppressed the unfolded protein response (UPR) such as IRE1 and PERK transcription, suggesting that KSHV achieves anti-apoptosis through the suppression of pro-apoptotic UPR. Furthermore, we found that diallyl trisulfide, methylseleninic acid, and sodium selenite are the novel and effective drugs against PEL.
|
